Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis announced positive Phase III REMODEL-1/-2 trial results for remibrutinib, a BTK inhibitor for relapsing multiple sclerosis. The drug showed superiority over teriflunomide in reducing annualized relapse rates and MRI lesions, with clinically meaningful disability progression delays and a favorable safety profile. Novartis plans to submit for regulatory approval globally.